ID   CBLB_HUMAN              Reviewed;         982 AA.
AC   Q13191; A8K9S7; B7WNM4; Q13192; Q13193; Q3LIC0; Q63Z43; Q8IVC5;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   07-FEB-2006, sequence version 2.
DT   07-APR-2021, entry version 220.
DE   RecName: Full=E3 ubiquitin-protein ligase CBL-B;
DE            EC=2.3.2.27 {ECO:0000269|PubMed:14661060, ECO:0000269|PubMed:20525694};
DE   AltName: Full=Casitas B-lineage lymphoma proto-oncogene b;
DE   AltName: Full=RING finger protein 56;
DE   AltName: Full=RING-type E3 ubiquitin transferase CBL-B {ECO:0000305};
DE   AltName: Full=SH3-binding protein CBL-B;
DE   AltName: Full=Signal transduction protein CBL-B;
GN   Name=CBLB; Synonyms=RNF56; ORFNames=Nbla00127;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS LONG; TRUNCATED 1 AND TRUNCATED 2).
RX   PubMed=7784085;
RA   Keane M.M., Rivero-Lezcano O.M., Mitchell J.A., Robbins K.C., Lipkowitz S.;
RT   "Cloning and characterization of cbl-b: a SH3 binding protein with homology
RT   to the c-cbl proto-oncogene.";
RL   Oncogene 10:2367-2377(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG), TISSUE SPECIFICITY, AND
RP   INTERACTION WITH VAV1.
RX   PubMed=9399639; DOI=10.1038/sj.onc.1201430;
RA   Bustelo X.R., Crespo P., Lopez-Barahona M., Gutkind J.S., Barbacid M.;
RT   "Cbl-b, a member of the Sli-1/c-Cbl protein family, inhibits Vav-mediated
RT   c-Jun N-terminal kinase activation.";
RL   Oncogene 15:2511-2520(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG).
RA   Shen C.-R., Chen Y.-J., Pai L.-M., Liu C.-L.;
RT   "Cbl-b in Taiwan population.";
RL   Submitted (DEC-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM LONG).
RC   TISSUE=Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J.,
RA   Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P.,
RA   Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A.,
RA   Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G.,
RA   Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W.,
RA   Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M.,
RA   Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P.,
RA   Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H.,
RA   Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J.,
RA   Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W.,
RA   Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B.,
RA   Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O.,
RA   Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X.,
RA   Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R.,
RA   Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM LONG), AND VARIANT LYS-584.
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 543-982 (ISOFORM LONG).
RC   TISSUE=Neuroblastoma;
RX   PubMed=12880961; DOI=10.1016/s0304-3835(03)00085-5;
RA   Ohira M., Morohashi A., Nakamura Y., Isogai E., Furuya K., Hamano S.,
RA   Machida T., Aoyama M., Fukumura M., Miyazaki K., Suzuki Y., Sugano S.,
RA   Hirato J., Nakagawara A.;
RT   "Neuroblastoma oligo-capping cDNA project: toward the understanding of the
RT   genesis and biology of neuroblastoma.";
RL   Cancer Lett. 197:63-68(2003).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 857-982 (ISOFORM LONG).
RC   TISSUE=Small intestine;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [10]
RP   TISSUE SPECIFICITY, MUTAGENESIS OF GLY-298; TYR-665 AND TYR-709,
RP   INTERACTION WITH GRB2 AND CRKL, PHOSPHORYLATION AT TYR-665 AND TYR-709, AND
RP   FUNCTION.
RX   PubMed=10022120; DOI=10.1038/sj.onc.1202411;
RA   Elly C., Witte S., Zhang Z., Rosnet O., Lipkowitz S., Altman A., Liu Y.-C.;
RT   "Tyrosine phosphorylation and complex formation of Cbl-b upon T cell
RT   receptor stimulation.";
RL   Oncogene 18:1147-1156(1999).
RN   [11]
RP   FUNCTION, PHOSPHORYLATION, AND INTERACTION WITH GRB2 AND PIK3R1.
RX   PubMed=10086340; DOI=10.1038/sj.onc.1202499;
RA   Ettenberg S.A., Keane M.M., Nau M.M., Frankel M., Wang L.-M., Pierce J.H.,
RA   Lipkowitz S.;
RT   "cbl-b inhibits epidermal growth factor receptor signaling.";
RL   Oncogene 18:1855-1866(1999).
RN   [12]
RP   FUNCTION, INTERACTION WITH PIK3R1, AND MUTAGENESIS OF GLY-298 AND CYS-373.
RX   PubMed=11087752; DOI=10.1074/jbc.m008901200;
RA   Fang D., Wang H.-Y., Fang N., Altman Y., Elly C., Liu Y.-C.;
RT   "Cbl-b, a RING-type E3 ubiquitin ligase, targets phosphatidylinositol 3-
RT   kinase for ubiquitination in T cells.";
RL   J. Biol. Chem. 276:4872-4878(2001).
RN   [13]
RP   UBIQUITINATION, AND MUTAGENESIS OF CYS-373.
RX   PubMed=11375397; DOI=10.1074/jbc.m102641200;
RA   Ettenberg S.A., Magnifico A., Cuello M., Nau M.M., Rubinstein Y.R.,
RA   Yarden Y., Weissman A.M., Lipkowitz S.;
RT   "Cbl-b-dependent coordinated degradation of the epidermal growth factor
RT   receptor signaling complex.";
RL   J. Biol. Chem. 276:27677-27684(2001).
RN   [14]
RP   FUNCTION.
RX   PubMed=11526404; DOI=10.1038/ni0901-870;
RA   Fang D., Liu Y.-C.;
RT   "Proteolysis-independent regulation of PI3K by Cbl-b-mediated
RT   ubiquitination in T cells.";
RL   Nat. Immunol. 2:870-875(2001).
RN   [15]
RP   INTERACTION WITH SH3KBP1, AND SUBCELLULAR LOCATION.
RX   PubMed=12177062; DOI=10.1074/jbc.m205535200;
RA   Szymkiewicz I., Kowanetz K., Soubeyran P., Dinarina A., Lipkowitz S.,
RA   Dikic I.;
RT   "CIN85 participates in Cbl-b-mediated down-regulation of receptor tyrosine
RT   kinases.";
RL   J. Biol. Chem. 277:39666-39672(2002).
RN   [16]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=14661060; DOI=10.1038/sj.onc.1207298;
RA   Kim M., Tezuka T., Tanaka K., Yamamoto T.;
RT   "Cbl-c suppresses v-Src-induced transformation through ubiquitin-dependent
RT   protein degradation.";
RL   Oncogene 23:1645-1655(2004).
RN   [17]
RP   INTERACTION WITH UBIQUITINATED PROTEINS, AND MUTAGENESIS OF 943-GLY-TYR-944
RP   AND LEU-967.
RX   PubMed=15273720; DOI=10.1038/sj.onc.1207952;
RA   Davies G.C., Ettenberg S.A., Coats A.O., Mussante M., Ravichandran S.,
RA   Collins J., Nau M.M., Lipkowitz S.;
RT   "Cbl-b interacts with ubiquitinated proteins; differential functions of the
RT   UBA domains of c-Cbl and Cbl-b.";
RL   Oncogene 23:7104-7115(2004).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-521; SER-525 AND SER-529, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [20]
RP   PHOSPHORYLATION AT SER-282.
RX   PubMed=19549985; DOI=10.1126/scisignal.2000046;
RA   Gruber T., Hermann-Kleiter N., Hinterleitner R., Fresser F., Schneider R.,
RA   Gastl G., Penninger J.M., Baier G.;
RT   "PKC-theta modulates the strength of T cell responses by targeting Cbl-b
RT   for ubiquitination and degradation.";
RL   Sci. Signal. 2:RA30-RA30(2009).
RN   [21]
RP   FUNCTION AS E3 UBIQUITIN-PROTEIN LIGASE, CATALYTIC ACTIVITY,
RP   PHOSPHORYLATION AT TYR-363, AND MUTAGENESIS OF TYR-363.
RX   PubMed=20525694; DOI=10.1074/jbc.m109.091157;
RA   Ryan P.E., Sivadasan-Nair N., Nau M.M., Nicholas S., Lipkowitz S.;
RT   "The N terminus of Cbl-c regulates ubiquitin ligase activity by modulating
RT   affinity for the ubiquitin-conjugating enzyme.";
RL   J. Biol. Chem. 285:23687-23698(2010).
RN   [22]
RP   INDUCTION, AND INTERACTION WITH IFT20 AND CBL.
RX   PubMed=29237719; DOI=10.1083/jcb.201611050;
RA   Schmid F.M., Schou K.B., Vilhelm M.J., Holm M.S., Breslin L., Farinelli P.,
RA   Larsen L.A., Andersen J.S., Pedersen L.B., Christensen S.T.;
RT   "IFT20 modulates ciliary PDGFRalpha signaling by regulating the stability
RT   of Cbl E3 ubiquitin ligases.";
RL   J. Cell Biol. 217:151-161(2018).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 899-914 IN COMPLEXES WITH SH3KBP1
RP   AND ARHGEF7, MUTAGENESIS OF ARG-904 AND ARG-911, AND SUBUNIT.
RX   PubMed=16228008; DOI=10.1038/nsmb1000;
RA   Jozic D., Cardenes N., Deribe Y.L., Moncalian G., Hoeller D., Groemping Y.,
RA   Dikic I., Rittinger K., Bravo J.;
RT   "Cbl promotes clustering of endocytic adaptor proteins.";
RL   Nat. Struct. Mol. Biol. 12:972-979(2005).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 902-912 IN COMPLEX WITH CD2AP,
RP   MUTAGENESIS OF ARG-904; LYS-907 AND ARG-911, AND SUBUNIT.
RX   PubMed=17020880; DOI=10.1074/jbc.m606411200;
RA   Moncalian G., Cardenes N., Deribe Y.L., Spinola-Amilibia M., Dikic I.,
RA   Bravo J.;
RT   "Atypical polyproline recognition by the CMS N-terminal Src homology 3
RT   domain.";
RL   J. Biol. Chem. 281:38845-38853(2006).
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (1.56 ANGSTROMS) OF 924-973 IN COMPLEX WITH
RP   UBIQUITIN, STRUCTURE BY NMR OF 924-973, TYROSINE PHOSPHORYLATION, AND
RP   MUTAGENESIS OF ALA-937; MET-940; PHE-946 AND ILE-966.
RX   PubMed=17679095; DOI=10.1016/j.molcel.2007.06.023;
RA   Peschard P., Kozlov G., Lin T., Mirza I.A., Berghuis A.M., Lipkowitz S.,
RA   Park M., Gehring K.;
RT   "Structural basis for ubiquitin-mediated dimerization and activation of the
RT   ubiquitin protein ligase Cbl-b.";
RL   Mol. Cell 27:474-485(2007).
RN   [26]
RP   STRUCTURE BY NMR OF 931-970.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of RSGI RUH-065, a UBA domain from human cDNA.";
RL   Submitted (MAY-2007) to the PDB data bank.
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (2.27 ANGSTROMS) OF 38-344 IN COMPLEX WITH
RP   PHOSPHO-EGFR PEPTIDE, INTERACTION WITH EGFR, AND HETERODIMER.
RG   Structural genomics consortium (SGC);
RT   "Crystal structure of Cbl-b TKB domain in complex with EGFR pY1069
RT   peptide.";
RL   Submitted (OCT-2010) to the PDB data bank.
CC   -!- FUNCTION: E3 ubiquitin-protein ligase which accepts ubiquitin from
CC       specific E2 ubiquitin-conjugating enzymes, and transfers it to
CC       substrates, generally promoting their degradation by the proteasome.
CC       Negatively regulates TCR (T-cell receptor), BCR (B-cell receptor) and
CC       FCER1 (high affinity immunoglobulin epsilon receptor) signal
CC       transduction pathways. In naive T-cells, inhibits VAV1 activation upon
CC       TCR engagement and imposes a requirement for CD28 costimulation for
CC       proliferation and IL-2 production. Also acts by promoting PIK3R1/p85
CC       ubiquitination, which impairs its recruitment to the TCR and subsequent
CC       activation. In activated T-cells, inhibits PLCG1 activation and calcium
CC       mobilization upon restimulation and promotes anergy. In B-cells, acts
CC       by ubiquitinating SYK and promoting its proteasomal degradation.
CC       Slightly promotes SRC ubiquitination. May be involved in EGFR
CC       ubiquitination and internalization. May be functionally coupled with
CC       the E2 ubiquitin-protein ligase UB2D3. In association with CBL,
CC       required for proper feedback inhibition of ciliary platelet-derived
CC       growth factor receptor-alpha (PDGFRA) signaling pathway via
CC       ubiquitination and internalization of PDGFRA (By similarity).
CC       {ECO:0000250|UniProtKB:Q3TTA7, ECO:0000269|PubMed:10022120,
CC       ECO:0000269|PubMed:10086340, ECO:0000269|PubMed:11087752,
CC       ECO:0000269|PubMed:11526404, ECO:0000269|PubMed:14661060,
CC       ECO:0000269|PubMed:20525694}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=S-ubiquitinyl-[E2 ubiquitin-conjugating enzyme]-L-cysteine +
CC         [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L-
CC         cysteine + N(6)-ubiquitinyl-[acceptor protein]-L-lysine.;
CC         EC=2.3.2.27; Evidence={ECO:0000269|PubMed:14661060,
CC         ECO:0000269|PubMed:20525694};
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Interacts with SH3 domain-containing proteins LCK, CRK and
CC       SORBS1. Interacts with LCP2 and ZAP70. Interacts with CBL
CC       (PubMed:29237719). Interacts with SH3 domain-containing proteins VAV1,
CC       FYN, FGR, PLCG1, GRB2, CRKL, PIK3R1 and SH3KBP1/CIN85. Identified in
CC       heterotrimeric complexes with SH3KBP1/CIN85, CD2AP and ARHGEF7, where
CC       one CBLB peptide binds two copies of the other protein. Interacts with
CC       poly-ubiquitinated proteins. Dimerization is required for the binding
CC       of poly-ubiquitin, but not for the binding of mono-ubiquitin. Interacts
CC       with EGFR (phosphorylated). Interacts with IFT20 (PubMed:29237719).
CC       {ECO:0000269|PubMed:10022120, ECO:0000269|PubMed:10086340,
CC       ECO:0000269|PubMed:11087752, ECO:0000269|PubMed:12177062,
CC       ECO:0000269|PubMed:15273720, ECO:0000269|PubMed:16228008,
CC       ECO:0000269|PubMed:17020880, ECO:0000269|PubMed:17679095,
CC       ECO:0000269|PubMed:29237719, ECO:0000269|PubMed:9399639,
CC       ECO:0000269|Ref.27}.
CC   -!- INTERACTION:
CC       Q13191; Q8IZP0: ABI1; NbExp=2; IntAct=EBI-744027, EBI-375446;
CC       Q13191; Q9ULH1: ASAP1; NbExp=2; IntAct=EBI-744027, EBI-346622;
CC       Q13191; Q9Y5K6: CD2AP; NbExp=11; IntAct=EBI-744027, EBI-298152;
CC       Q13191; P46108: CRK; NbExp=4; IntAct=EBI-744027, EBI-886;
CC       Q13191; P46109: CRKL; NbExp=4; IntAct=EBI-744027, EBI-910;
CC       Q13191; O75190: DNAJB6; NbExp=3; IntAct=EBI-744027, EBI-1053164;
CC       Q13191; Q01658: DR1; NbExp=3; IntAct=EBI-744027, EBI-750300;
CC       Q13191; P35637: FUS; NbExp=3; IntAct=EBI-744027, EBI-400434;
CC       Q13191; P06241-3: FYN; NbExp=4; IntAct=EBI-744027, EBI-10691738;
CC       Q13191; O76003: GLRX3; NbExp=3; IntAct=EBI-744027, EBI-374781;
CC       Q13191; Q9H8Y8: GORASP2; NbExp=8; IntAct=EBI-744027, EBI-739467;
CC       Q13191; P62993: GRB2; NbExp=26; IntAct=EBI-744027, EBI-401755;
CC       Q13191; Q00403: GTF2B; NbExp=3; IntAct=EBI-744027, EBI-389564;
CC       Q13191; Q9Y5Q9: GTF3C3; NbExp=3; IntAct=EBI-744027, EBI-1054873;
CC       Q13191; Q5S007: LRRK2; NbExp=4; IntAct=EBI-744027, EBI-5323863;
CC       Q13191; P16333: NCK1; NbExp=4; IntAct=EBI-744027, EBI-389883;
CC       Q13191; O43639: NCK2; NbExp=8; IntAct=EBI-744027, EBI-713635;
CC       Q13191; P35240-4: NF2; NbExp=3; IntAct=EBI-744027, EBI-1014514;
CC       Q13191; P55345: PRMT2; NbExp=3; IntAct=EBI-744027, EBI-78458;
CC       Q13191; Q13882: PTK6; NbExp=3; IntAct=EBI-744027, EBI-1383632;
CC       Q13191; Q96B97: SH3KBP1; NbExp=22; IntAct=EBI-744027, EBI-346595;
CC       Q13191; P00441: SOD1; NbExp=3; IntAct=EBI-744027, EBI-990792;
CC       Q13191; O94875-10: SORBS2; NbExp=3; IntAct=EBI-744027, EBI-12037893;
CC       Q13191; Q6NUL7: SPTLC1; NbExp=3; IntAct=EBI-744027, EBI-25912847;
CC       Q13191; Q13148: TARDBP; NbExp=6; IntAct=EBI-744027, EBI-372899;
CC       Q13191; P57075-2: UBASH3A; NbExp=3; IntAct=EBI-744027, EBI-7353612;
CC       Q13191; Q8TF42: UBASH3B; NbExp=6; IntAct=EBI-744027, EBI-1380492;
CC       Q13191; Q9UKW4: VAV3; NbExp=3; IntAct=EBI-744027, EBI-297568;
CC       Q13191; O14972: VPS26C; NbExp=3; IntAct=EBI-744027, EBI-7207091;
CC       Q13191; P07947: YES1; NbExp=3; IntAct=EBI-744027, EBI-515331;
CC       Q13191-1; Q9BXL7: CARD11; NbExp=4; IntAct=EBI-15555129, EBI-7006141;
CC       Q13191-1; Q96B97-1: SH3KBP1; NbExp=3; IntAct=EBI-15555129, EBI-7585212;
CC       Q13191-1; P62837: UBE2D2; NbExp=2; IntAct=EBI-15555129, EBI-347677;
CC       Q13191-1; O55043: Arhgef7; Xeno; NbExp=2; IntAct=EBI-15555129, EBI-3649585;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:12177062}.
CC       Note=Upon EGF stimulation, associates with endocytic vesicles.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=Long;
CC         IsoId=Q13191-1; Sequence=Displayed;
CC       Name=Truncated 1;
CC         IsoId=Q13191-2; Sequence=VSP_005729;
CC       Name=Truncated 2;
CC         IsoId=Q13191-3; Sequence=VSP_005730, VSP_005731;
CC   -!- TISSUE SPECIFICITY: Expressed in placenta, heart, lung, kidney, spleen,
CC       ovary and testis, as well as fetal brain and liver and hematopoietic
CC       cell lines, but not in adult brain, liver, pancreas, salivary gland, or
CC       skeletal muscle. Present in lymphocytes (at protein level).
CC       {ECO:0000269|PubMed:10022120, ECO:0000269|PubMed:9399639}.
CC   -!- INDUCTION: By serum starvation. {ECO:0000269|PubMed:29237719}.
CC   -!- DOMAIN: The N-terminus is composed of the phosphotyrosine binding (PTB)
CC       domain, a short linker region and the RING-type zinc finger. The PTB
CC       domain, which is also called TKB (tyrosine kinase binding) domain, is
CC       composed of three different subdomains: a four-helix bundle (4H), a
CC       calcium-binding EF hand and a divergent SH2 domain.
CC   -!- DOMAIN: The RING-type zinc finger domain mediates binding to an E2
CC       ubiquitin-conjugating enzyme.
CC   -!- DOMAIN: The UBA domain interacts with poly-ubiquitinated proteins.
CC   -!- PTM: Phosphorylated on tyrosine and serine residues upon TCR or BCR
CC       activation, and upon various types of cell stimulation.
CC       {ECO:0000269|PubMed:10022120, ECO:0000269|PubMed:10086340,
CC       ECO:0000269|PubMed:19549985, ECO:0000269|PubMed:20525694}.
CC   -!- PTM: Auto-ubiquitinated upon EGF-mediated cell activation or upon T-
CC       cell costimulation by CD28; which promotes proteasomal degradation.
CC       {ECO:0000269|PubMed:11375397}.
CC   -!- MISCELLANEOUS: This protein has one functional calcium-binding site.
CC       {ECO:0000250}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAE45748.1; Type=Erroneous termination; Note=Truncated C-terminus.; Evidence={ECO:0000305};
CC       Sequence=CAH56175.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/CBLbID193.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U26710; AAB09291.1; -; mRNA.
DR   EMBL; U26711; AAB09292.1; -; mRNA.
DR   EMBL; U26712; AAB09293.1; -; mRNA.
DR   EMBL; DQ349203; ABC86700.1; -; mRNA.
DR   EMBL; AK292792; BAF85481.1; -; mRNA.
DR   EMBL; AC016138; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471052; EAW79752.1; -; Genomic_DNA.
DR   EMBL; CH471052; EAW79753.1; -; Genomic_DNA.
DR   EMBL; CH471052; EAW79754.1; -; Genomic_DNA.
DR   EMBL; BC032851; AAH32851.1; -; mRNA.
DR   EMBL; AB075490; BAE45748.1; ALT_SEQ; mRNA.
DR   EMBL; BX537484; CAH56175.1; ALT_SEQ; mRNA.
DR   CCDS; CCDS2948.1; -. [Q13191-1]
DR   RefSeq; NP_001308717.1; NM_001321788.1. [Q13191-1]
DR   RefSeq; NP_733762.2; NM_170662.4. [Q13191-1]
DR   RefSeq; XP_011511559.1; XM_011513257.1. [Q13191-1]
DR   PDB; 2AK5; X-ray; 1.85 A; D=904-911.
DR   PDB; 2BZ8; X-ray; 2.00 A; C=902-912.
DR   PDB; 2DO6; NMR; -; A/B=931-970.
DR   PDB; 2J6F; X-ray; 1.70 A; C=902-912.
DR   PDB; 2JNH; NMR; -; A=926-971.
DR   PDB; 2LDR; NMR; -; A=351-426.
DR   PDB; 2OOA; X-ray; 1.56 A; A/B=924-973.
DR   PDB; 2OOB; X-ray; 1.90 A; A=924-973.
DR   PDB; 3PFV; X-ray; 2.27 A; A/B=38-344.
DR   PDB; 3VGO; X-ray; 3.10 A; A/B/C=39-426.
DR   PDB; 3ZNI; X-ray; 2.21 A; A/E/I/M=36-427.
DR   PDBsum; 2AK5; -.
DR   PDBsum; 2BZ8; -.
DR   PDBsum; 2DO6; -.
DR   PDBsum; 2J6F; -.
DR   PDBsum; 2JNH; -.
DR   PDBsum; 2LDR; -.
DR   PDBsum; 2OOA; -.
DR   PDBsum; 2OOB; -.
DR   PDBsum; 3PFV; -.
DR   PDBsum; 3VGO; -.
DR   PDBsum; 3ZNI; -.
DR   BMRB; Q13191; -.
DR   SMR; Q13191; -.
DR   BioGRID; 107316; 87.
DR   CORUM; Q13191; -.
DR   DIP; DIP-33091N; -.
DR   IntAct; Q13191; 67.
DR   MINT; Q13191; -.
DR   STRING; 9606.ENSP00000264122; -.
DR   iPTMnet; Q13191; -.
DR   PhosphoSitePlus; Q13191; -.
DR   BioMuta; CBLB; -.
DR   DMDM; 88911265; -.
DR   EPD; Q13191; -.
DR   jPOST; Q13191; -.
DR   MassIVE; Q13191; -.
DR   MaxQB; Q13191; -.
DR   PaxDb; Q13191; -.
DR   PeptideAtlas; Q13191; -.
DR   PRIDE; Q13191; -.
DR   ProteomicsDB; 59215; -. [Q13191-1]
DR   ProteomicsDB; 59216; -. [Q13191-2]
DR   ProteomicsDB; 59217; -. [Q13191-3]
DR   Antibodypedia; 16015; 252 antibodies.
DR   DNASU; 868; -.
DR   Ensembl; ENST00000394030; ENSP00000377598; ENSG00000114423. [Q13191-1]
DR   Ensembl; ENST00000403724; ENSP00000384816; ENSG00000114423. [Q13191-3]
DR   Ensembl; ENST00000405772; ENSP00000384938; ENSG00000114423. [Q13191-2]
DR   GeneID; 868; -.
DR   KEGG; hsa:868; -.
DR   UCSC; uc003dwc.4; human. [Q13191-1]
DR   CTD; 868; -.
DR   DisGeNET; 868; -.
DR   GeneCards; CBLB; -.
DR   HGNC; HGNC:1542; CBLB.
DR   HPA; ENSG00000114423; Low tissue specificity.
DR   MIM; 604491; gene.
DR   neXtProt; NX_Q13191; -.
DR   OpenTargets; ENSG00000114423; -.
DR   PharmGKB; PA26116; -.
DR   VEuPathDB; HostDB:ENSG00000114423.18; -.
DR   eggNOG; KOG1785; Eukaryota.
DR   GeneTree; ENSGT00940000156631; -.
DR   HOGENOM; CLU_013535_3_0_1; -.
DR   InParanoid; Q13191; -.
DR   OMA; REFACFP; -.
DR   OrthoDB; 540689at2759; -.
DR   PhylomeDB; Q13191; -.
DR   TreeFam; TF314210; -.
DR   BRENDA; 6.3.2.19; 2681.
DR   PathwayCommons; Q13191; -.
DR   Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation.
DR   SignaLink; Q13191; -.
DR   SIGNOR; Q13191; -.
DR   UniPathway; UPA00143; -.
DR   BioGRID-ORCS; 868; 18 hits in 999 CRISPR screens.
DR   ChiTaRS; CBLB; human.
DR   EvolutionaryTrace; Q13191; -.
DR   GeneWiki; CBLB_(gene); -.
DR   GenomeRNAi; 868; -.
DR   Pharos; Q13191; Tbio.
DR   PRO; PR:Q13191; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; Q13191; protein.
DR   Bgee; ENSG00000114423; Expressed in pericardium and 227 other tissues.
DR   ExpressionAtlas; Q13191; baseline and differential.
DR   Genevisible; Q13191; HS.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0045121; C:membrane raft; IBA:GO_Central.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0001784; F:phosphotyrosine residue binding; IEA:InterPro.
DR   GO; GO:0030971; F:receptor tyrosine kinase binding; IBA:GO_Central.
DR   GO; GO:0017124; F:SH3 domain binding; IBA:GO_Central.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IBA:GO_Central.
DR   GO; GO:0008270; F:zinc ion binding; TAS:ProtInc.
DR   GO; GO:0006955; P:immune response; IEA:Ensembl.
DR   GO; GO:0035556; P:intracellular signal transduction; IEA:Ensembl.
DR   GO; GO:0046642; P:negative regulation of alpha-beta T cell proliferation; IEA:Ensembl.
DR   GO; GO:0007175; P:negative regulation of epidermal growth factor-activated receptor activity; IBA:GO_Central.
DR   GO; GO:0050860; P:negative regulation of T cell receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0006607; P:NLS-bearing protein import into nucleus; TAS:ProtInc.
DR   GO; GO:0018193; P:peptidyl-amino acid modification; IEA:Ensembl.
DR   GO; GO:0045732; P:positive regulation of protein catabolic process; IEA:Ensembl.
DR   GO; GO:0031398; P:positive regulation of protein ubiquitination; IEA:Ensembl.
DR   GO; GO:0002669; P:positive regulation of T cell anergy; IEA:Ensembl.
DR   GO; GO:0043087; P:regulation of GTPase activity; IEA:Ensembl.
DR   GO; GO:2000583; P:regulation of platelet-derived growth factor receptor-alpha signaling pathway; ISS:UniProtKB.
DR   GO; GO:0043393; P:regulation of protein binding; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; IBA:GO_Central.
DR   GO; GO:0042110; P:T cell activation; IEA:Ensembl.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; IEA:Ensembl.
DR   CDD; cd16709; RING-HC_Cbl-b; 1.
DR   CDD; cd09920; SH2_Cbl-b_TKB; 1.
DR   Gene3D; 1.20.930.20; -; 1.
DR   Gene3D; 3.30.40.10; -; 1.
DR   Gene3D; 3.30.505.10; -; 1.
DR   IDEAL; IID00319; -.
DR   InterPro; IPR024162; Adaptor_Cbl.
DR   InterPro; IPR014741; Adaptor_Cbl_EF_hand-like.
DR   InterPro; IPR036537; Adaptor_Cbl_N_dom_sf.
DR   InterPro; IPR003153; Adaptor_Cbl_N_hlx.
DR   InterPro; IPR014742; Adaptor_Cbl_SH2-like.
DR   InterPro; IPR039520; CBL-B_RING-HC.
DR   InterPro; IPR024159; Cbl_PTB.
DR   InterPro; IPR011992; EF-hand-dom_pair.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   InterPro; IPR015940; UBA.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   InterPro; IPR017907; Znf_RING_CS.
DR   PANTHER; PTHR23007; PTHR23007; 1.
DR   Pfam; PF02262; Cbl_N; 1.
DR   Pfam; PF02761; Cbl_N2; 1.
DR   Pfam; PF02762; Cbl_N3; 1.
DR   SMART; SM00184; RING; 1.
DR   SMART; SM00165; UBA; 1.
DR   SUPFAM; SSF47473; SSF47473; 1.
DR   SUPFAM; SSF47668; SSF47668; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   PROSITE; PS51506; CBL_PTB; 1.
DR   PROSITE; PS50030; UBA; 1.
DR   PROSITE; PS00518; ZF_RING_1; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Cytoplasm; Metal-binding;
KW   Phosphoprotein; Reference proteome; Repeat; Transferase; Ubl conjugation;
KW   Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN           1..982
FT                   /note="E3 ubiquitin-protein ligase CBL-B"
FT                   /id="PRO_0000055860"
FT   DOMAIN          35..343
FT                   /note="Cbl-PTB"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00839"
FT   DOMAIN          931..970
FT                   /note="UBA"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00212"
FT   CA_BIND         219..232
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00839"
FT   ZN_FING         373..412
FT                   /note="RING-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00175"
FT   REGION          35..167
FT                   /note="4H"
FT   REGION          168..240
FT                   /note="EF-hand-like"
FT   REGION          241..343
FT                   /note="SH2-like"
FT   REGION          344..372
FT                   /note="Linker"
FT   REGION          543..568
FT                   /note="Interaction with VAV1"
FT                   /evidence="ECO:0000269|PubMed:9399639"
FT   REGION          891..927
FT                   /note="Interaction with SH3KBP1"
FT                   /evidence="ECO:0000269|PubMed:12177062"
FT   COMPBIAS        477..925
FT                   /note="Pro-rich"
FT   BINDING         286
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         282
FT                   /note="Phosphoserine; by PKC/PRKCQ"
FT                   /evidence="ECO:0000269|PubMed:19549985"
FT   MOD_RES         363
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000305|PubMed:20525694"
FT   MOD_RES         476
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K4S7"
FT   MOD_RES         480
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q3TTA7"
FT   MOD_RES         484
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q3TTA7"
FT   MOD_RES         521
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         525
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         529
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         634
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8K4S7"
FT   MOD_RES         665
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:10022120"
FT   MOD_RES         709
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:10022120"
FT   MOD_RES         889
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q3TTA7"
FT   VAR_SEQ         767..770
FT                   /note="DVFD -> TYRI (in isoform Truncated 2)"
FT                   /evidence="ECO:0000303|PubMed:7784085"
FT                   /id="VSP_005730"
FT   VAR_SEQ         771..982
FT                   /note="Missing (in isoform Truncated 2)"
FT                   /evidence="ECO:0000303|PubMed:7784085"
FT                   /id="VSP_005731"
FT   VAR_SEQ         811..982
FT                   /note="Missing (in isoform Truncated 1)"
FT                   /evidence="ECO:0000303|PubMed:7784085"
FT                   /id="VSP_005729"
FT   VARIANT         584
FT                   /note="R -> K (in dbSNP:rs17853100)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_025303"
FT   VARIANT         883
FT                   /note="N -> D (in dbSNP:rs35835913)"
FT                   /id="VAR_039241"
FT   MUTAGEN         298
FT                   /note="G->E: Inhibits interaction with SYK. No effect on E3
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:10022120,
FT                   ECO:0000269|PubMed:11087752"
FT   MUTAGEN         363
FT                   /note="Y->E: Decreases affinity for E2 ubiquitin-
FT                   conjugating enzymes."
FT                   /evidence="ECO:0000269|PubMed:20525694"
FT   MUTAGEN         373
FT                   /note="C->A: Abolishes E3 activity but does not affect
FT                   binding to substrates."
FT                   /evidence="ECO:0000269|PubMed:11087752,
FT                   ECO:0000269|PubMed:11375397"
FT   MUTAGEN         665
FT                   /note="Y->F: Slightly inhibits interaction with CRKL.
FT                   Abolishes interaction with CRKL; when associated with F-
FT                   709."
FT                   /evidence="ECO:0000269|PubMed:10022120"
FT   MUTAGEN         709
FT                   /note="Y->F: Inhibits interaction with CRKL. Abolishes
FT                   interaction with CRKL; when associated with F-665."
FT                   /evidence="ECO:0000269|PubMed:10022120"
FT   MUTAGEN         904
FT                   /note="R->A: No effect on interaction with CD2AP. Reduced
FT                   interaction with SH3KBP1. Strongly reduced interaction with
FT                   SH3KBP1; when associated with A-911."
FT                   /evidence="ECO:0000269|PubMed:16228008,
FT                   ECO:0000269|PubMed:17020880"
FT   MUTAGEN         907
FT                   /note="K->A: No effect on interaction with SH3KBP1. Reduced
FT                   interaction with CD2AP. Strongly reduced interaction with
FT                   CD2AP; when associated with A-911."
FT                   /evidence="ECO:0000269|PubMed:17020880"
FT   MUTAGEN         911
FT                   /note="R->A: Reduced interaction with CD2AP and with
FT                   SH3KBP1. Strongly reduced interaction with CD2AP; when
FT                   associated with A-907. Strongly reduced interaction with
FT                   SH3KBP1; when associated with A-904."
FT                   /evidence="ECO:0000269|PubMed:16228008,
FT                   ECO:0000269|PubMed:17020880"
FT   MUTAGEN         937
FT                   /note="A->E: Loss of ubiquitin binding. Reduced levels of
FT                   tyrosine phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:17679095"
FT   MUTAGEN         940
FT                   /note="M->A: Loss of ubiquitin binding. Reduced levels of
FT                   tyrosine phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:17679095"
FT   MUTAGEN         943..944
FT                   /note="GY->AQ: Abolishes interaction with ubiquitinated
FT                   proteins."
FT                   /evidence="ECO:0000269|PubMed:15273720"
FT   MUTAGEN         946
FT                   /note="F->A: Loss of ubiquitin binding. Reduced levels of
FT                   tyrosine phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:17679095"
FT   MUTAGEN         966
FT                   /note="I->E: Interferes with dimerization. Reduced E3
FT                   ubiquitin-protein ligase activity. Reduced levels of
FT                   tyrosine phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:17679095"
FT   MUTAGEN         967
FT                   /note="L->A: No effect on interaction with ubiquitinated
FT                   proteins."
FT                   /evidence="ECO:0000269|PubMed:15273720"
FT   CONFLICT        210
FT                   /note="G -> S (in Ref. 1; AAB09291/AAB09292/AAB09293)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        911
FT                   /note="R -> C (in Ref. 9; CAH56175)"
FT                   /evidence="ECO:0000305"
FT   HELIX           43..60
FT                   /evidence="ECO:0007744|PDB:3ZNI"
FT   HELIX           63..65
FT                   /evidence="ECO:0007744|PDB:3ZNI"
FT   STRAND          69..72
FT                   /evidence="ECO:0007744|PDB:3ZNI"
FT   HELIX           74..91
FT                   /evidence="ECO:0007744|PDB:3ZNI"
FT   HELIX           95..102
FT                   /evidence="ECO:0007744|PDB:3ZNI"
FT   HELIX           105..128
FT                   /evidence="ECO:0007744|PDB:3ZNI"
FT   HELIX           129..133
FT                   /evidence="ECO:0007744|PDB:3ZNI"
FT   HELIX           138..160
FT                   /evidence="ECO:0007744|PDB:3ZNI"
FT   HELIX           162..164
FT                   /evidence="ECO:0007744|PDB:3ZNI"
FT   HELIX           168..170
FT                   /evidence="ECO:0007744|PDB:3ZNI"
FT   HELIX           176..186
FT                   /evidence="ECO:0007744|PDB:3ZNI"
FT   STRAND          190..193
FT                   /evidence="ECO:0007744|PDB:3ZNI"
FT   HELIX           194..204
FT                   /evidence="ECO:0007744|PDB:3ZNI"
FT   HELIX           210..220
FT                   /evidence="ECO:0007744|PDB:3ZNI"
FT   STRAND          225..229
FT                   /evidence="ECO:0007744|PDB:3ZNI"
FT   HELIX           230..239
FT                   /evidence="ECO:0007744|PDB:3ZNI"
FT   HELIX           243..245
FT                   /evidence="ECO:0007744|PDB:3ZNI"
FT   HELIX           246..253
FT                   /evidence="ECO:0007744|PDB:3ZNI"
FT   STRAND          260..263
FT                   /evidence="ECO:0007744|PDB:3VGO"
FT   HELIX           266..273
FT                   /evidence="ECO:0007744|PDB:3ZNI"
FT   HELIX           274..276
FT                   /evidence="ECO:0007744|PDB:3ZNI"
FT   STRAND          282..287
FT                   /evidence="ECO:0007744|PDB:3ZNI"
FT   STRAND          289..291
FT                   /evidence="ECO:0007744|PDB:3ZNI"
FT   STRAND          295..300
FT                   /evidence="ECO:0007744|PDB:3ZNI"
FT   STRAND          306..309
FT                   /evidence="ECO:0007744|PDB:3ZNI"
FT   STRAND          312..314
FT                   /evidence="ECO:0007744|PDB:3PFV"
FT   HELIX           316..325
FT                   /evidence="ECO:0007744|PDB:3ZNI"
FT   HELIX           332..334
FT                   /evidence="ECO:0007744|PDB:3VGO"
FT   HELIX           342..344
FT                   /evidence="ECO:0007744|PDB:3PFV"
FT   STRAND          352..354
FT                   /evidence="ECO:0007744|PDB:3ZNI"
FT   HELIX           357..364
FT                   /evidence="ECO:0007744|PDB:3ZNI"
FT   TURN            365..367
FT                   /evidence="ECO:0007744|PDB:3ZNI"
FT   STRAND          370..372
FT                   /evidence="ECO:0007744|PDB:3ZNI"
FT   TURN            374..376
FT                   /evidence="ECO:0007744|PDB:3ZNI"
FT   STRAND          377..380
FT                   /evidence="ECO:0007744|PDB:3ZNI"
FT   STRAND          383..386
FT                   /evidence="ECO:0007744|PDB:3ZNI"
FT   HELIX           394..402
FT                   /evidence="ECO:0007744|PDB:3ZNI"
FT   TURN            409..411
FT                   /evidence="ECO:0007744|PDB:3ZNI"
FT   STRAND          417..420
FT                   /evidence="ECO:0007744|PDB:3ZNI"
FT   STRAND          422..424
FT                   /evidence="ECO:0007744|PDB:3ZNI"
FT   HELIX           933..941
FT                   /evidence="ECO:0007744|PDB:2OOA"
FT   HELIX           946..955
FT                   /evidence="ECO:0007744|PDB:2OOA"
FT   TURN            956..958
FT                   /evidence="ECO:0007744|PDB:2OOA"
FT   HELIX           960..970
FT                   /evidence="ECO:0007744|PDB:2OOA"
SQ   SEQUENCE   982 AA;  109450 MW;  B4E307D31B9F0779 CRC64;
     MANSMNGRNP GGRGGNPRKG RILGIIDAIQ DAVGPPKQAA ADRRTVEKTW KLMDKVVRLC
     QNPKLQLKNS PPYILDILPD TYQHLRLILS KYDDNQKLAQ LSENEYFKIY IDSLMKKSKR
     AIRLFKEGKE RMYEEQSQDR RNLTKLSLIF SHMLAEIKAI FPNGQFQGDN FRITKADAAE
     FWRKFFGDKT IVPWKVFRQC LHEVHQISSG LEAMALKSTI DLTCNDYISV FEFDIFTRLF
     QPWGSILRNW NFLAVTHPGY MAFLTYDEVK ARLQKYSTKP GSYIFRLSCT RLGQWAIGYV
     TGDGNILQTI PHNKPLFQAL IDGSREGFYL YPDGRSYNPD LTGLCEPTPH DHIKVTQEQY
     ELYCEMGSTF QLCKICAEND KDVKIEPCGH LMCTSCLTAW QESDGQGCPF CRCEIKGTEP
     IIVDPFDPRD EGSRCCSIID PFGMPMLDLD DDDDREESLM MNRLANVRKC TDRQNSPVTS
     PGSSPLAQRR KPQPDPLQIP HLSLPPVPPR LDLIQKGIVR SPCGSPTGSP KSSPCMVRKQ
     DKPLPAPPPP LRDPPPPPPE RPPPIPPDNR LSRHIHHVES VPSRDPPMPL EAWCPRDVFG
     TNQLVGCRLL GEGSPKPGIT ASSNVNGRHS RVGSDPVLMR KHRRHDLPLE GAKVFSNGHL
     GSEEYDVPPR LSPPPPVTTL LPSIKCTGPL ANSLSEKTRD PVEEDDDEYK IPSSHPVSLN
     SQPSHCHNVK PPVRSCDNGH CMLNGTHGPS SEKKSNIPDL SIYLKGDVFD SASDPVPLPP
     ARPPTRDNPK HGSSLNRTPS DYDLLIPPLG EDAFDALPPS LPPPPPPARH SLIEHSKPPG
     SSSRPSSGQD LFLLPSDPFV DLASGQVPLP PARRLPGENV KTNRTSQDYD QLPSCSDGSQ
     APARPPKPRP RRTAPEIHHR KPHGPEAALE NVDAKIAKLM GEGYAFEEVK RALEIAQNNV
     EVARSILREF AFPPPVSPRL NL
//
